Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-Analysis
February 2022
in “
JAMA Dermatology
”
Studysummary This meta-analysis found that spironolactone use was linked to a decreased risk of prostate cancer but not to a significant risk increase for several other cancers, although the evidence certainty was low.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jamanetwork.com →